Bristol Myers Squibb And Blue Spark Technologies Partner-Up To Use TempTraq wearable in CAR T Patient Monitoring

TempTraq Being Used in observational trial
Photo: Business Wire

Blue Spark Technologies, Inc. today announced that Bristol Myers Squibb will use its TempTraq wearable Bluetooth continuous body temperature monitoring platform in a U.S. observational trial to monitor patients across multiple BMS CAR T assets prior to and following CAR T patients’ infusion with the cell therapy. This observational trial will be Bristol Myers Squibb’s first use of a remote patient monitoring technology to track CAR T patient temperatures, which can be a sign of cytokine release syndrome (CRS), a common side effect observed within the CAR T category of therapies.

Read more TempTraq Single-Use Disposable Patch Ideal for Remote Monitoring of Coronavirus Patients

In the partnership, Blue Spark Technologies will supply the TempTraq wearable device for use by patients with multiple myeloma or lymphoma who are participating in the observational trial to receive a Bristol Myers Squibb CAR T product. The trial represents a first step to explore how technologies like TempTraq, paired with clinical, disease state and scientific expertise can inform next-generation products aimed at supporting specific patient situations such as post-CAR T infusion.

In the observational trial, the innovative temperature technology will provide real-time, continuous temperature data to patients and their clinicians so they can co-monitor for fever, which is one of the early signs of CRS, according to a press release.

“As we progress into next-generation therapeutics like CAR T cell therapies, patient-centric technologies like TempTraq will become supportive components in creating an ecosystem where the promise of cell therapy can thrive,” said Sarah Hersey, vice president, Precision Medicine at Bristol Myers Squibb.

Bristol Myers Squibb office
Photo: Jonathan Schilling, Wikimedia Commons

“We are honored that BMS has decided to partner with Blue Spark on this cutting-edge solution,” said John Gannon, Blue Spark President and Chief Executive Officer.

The TempTraq wearable device will be used at as many as 12 BMS cell therapy clinical trial sites across the U.S.

About TempTraq

TempTraq, Blue Spark Technologies’ patented innovation, is the only disposable Bluetooth, wearable temperature monitor in the form of a soft, comfortable patch that continuously, safely and comfortably monitors body temperature for up to 72 hours and sends notifications to Apple or Android compatible mobile devices.

Read more Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate on AFib Diagnosis

TempTraq Connect is the HIPAA-compliant cloud service supported by Google Healthcare Cloud Platform that enables patients and caregivers to monitor body temperature from anywhere. It can also directly integrate with healthcare provider electronic medical record (EMR) systems and nurse monitoring stations, providing a secure method of storing patient healthcare data. The system is FDA, CE and TGA cleared.

Previous articleSamsung’s LPDDR5 UFS-Based Multichip Package Delivers Highest Performance To Make 5G Accessible To Smartphone Users
Next articleDarioHealth Launches Upright GO S, A Wearable Intended to Suppress Slouching and Boost Better Posture
Cathy Russey
Cathy Russey () is Online Editor at WT | Wearable Technologies and specialized in writing about the latest medical wearables and enabling technologies on the market. Cathy can be contacted at info(at)